Table 5.

Follow-up study

Case No.	Main medication	Dietary pattern				Days of remission	Reason for termination	On final attendance
		Month 3	Year 1	Year 2	On relapse			CDAI	CRP (mg/dL)	BMI (kg/m2)	Alb (g/dL)	Chol (mg/dL)	ChE (IU/mL)	Hemoglobin (g/dL)
1	SSZ for 1 yr	SVD	SVD	SVD		730	Completion	0	0.1	23.1	4.5	235	5684	14.4
2	Mesalamine	SVD	Omni		Omni	301	Relapse	193	8.2	17.5	3.8	151	3262	13.8
3	Mesalamine	SVD	Omni		Omni	367	Relapse	167	11.3	21.1	3.5	133	3551	10.0
4	Mesalamine	SVD	SVD	SVD		730	Completion	128	5.0	18.7	2.8	114	1113	9.3
5	SSZ for 1 yr	SVD	SVD			523	Moving	39	0	19.4	4.5	194	5509	15.0
6	Mesalamine	Omni			Omni	191	Relapse	192	5.7	21.7	3.9	134	3052	7.9
7	None	SVD	SVD			442	INFX for RA	61	2.0	19.6	4.0	158	5068	10.9
8	Mesalamine	SVD	SVD		SVD	635	Relapse	174	7.6	19.1	3.1	88	2678	11.3
9	Mesalamine	Omni	Omni	Omni		730	Completion	48	0.2	19.8	4.3	171	5461	15.2
10	Mesalamine	SVD	SVD	SVD		730	Completion	18	0.1	18.2	5.1	181	4659	16.3
11	Mesalamine	SVD	SVD	SVD		730	Completion	11	0	19.7	4.7	147	5215	13.9
12	Mesalamine	SVD	SVD	SVD		730	Completion	45	0	20.2	4.7	163	6268	11.3
13	Mesalamine	SVD	SVD	SVD		730	Completion	0	0	22.8	4.6	171	4770	15.6
14	Mesalamine	SVD	SVD			666	Ongoing	27	0.1	19.3	4.7	188	6084	15.1
15	Mesalamine	SVD	Omni			560	Ongoing	0	0	22.6	4.8	185	5671	16.8
16	Mesalamine	SVD	SVD			440	Ongoing	19	1.9	21.8	4.4	141	5146	14.2
17	Mesalamine	SVD	SVD			397	Ongoing	32	2.0	22.5	3.6	216	2683	11.1
18	Mesalamine	SVD	SVD	SVD		730	Completion	25	0.4	22.6	3.7	151	10222	11.1
19	Mesalamine	SVD	SVD	SVD		730	Completion	62	0	20.1	4.7	139	4391	13.3
20	None	SVD	SVD	SVD		730	Completion	37	0.7	18.2	4.5	156	5655	13.2
21	SSZ	SVD	SVD	SVD		730	Completion	16	0.1	19.0	4.9	205	6424	14.4
22	Mesalamine	SVD	Omni		Omni	630	Relapse	118	5.1	22.1	3.5	84	3596	10.1

Alb: Albumin; SSZ: Sulfasalazine; Omni: Omnivorous diet; INFX: Infliximab; RA: Rheumatoid arthritis. Normal range: CRP: ≤ 0.3 mg/dL; BMI: 18.5 kg/m² ≤-< 25.0 kg/m²; Albmin: 3.8-5.2 g/dL; Chol: 120-220 mg/dL; ChE: 3200-6500 IU/mL; Hemoglobin: M: 13.8-17.5 g/dL, F: 12.0-15.1 g/dL.